Immune checkpoint inhibitor associated bullous pemphigoid: A single-centre retrospective study
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Immune-checkpoint inhibitors (ICIs) have revolutionized cancer therapy over the past decade. Among immune-related adverse events (irAEs) associated with ICIs, cutaneous manifestations are common. These range from mild pruritus to autoimmune blistering diseases like bullous pemphigoid (BP). BP, though relatively rare, can represent a severe irAE often necessitating treatment discontinuation. Despite its significance, relevant literature remains limited.
Source: EJC Skin Cancer
Institution: National and Kapodistrian University of Athens
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409145098